What is Mercaptopurine? Mercaptopurine (6-mercaptopurine or 6-MP) is an analog of the purine bases adenine and guanine, acting as a purine antimetabolite antineoplastic agent. Approved by the US FDA in 1953, it was one of the earliest chemotherapy agents developed. It remains a core component of maintenance therapy for acute lymphoblastic leukemia (ALL) and is also used off-label as an immunosuppressive agent in inflammatory bowel diseases (Crohn’s disease and ulcerative colitis). As a cytotoxic agent, Mercaptopurine requires precise dosing and therapeutic drug monitoring. The discovery of genetic variations in its metabolism was a major milestone in pharmacogenomics, allowing for personalized dosing to prevent severe, life-threatening toxicities. Mechanism of Action Mercaptopurine is an inactive prodrug that must enter target cells and undergo intracellular metabolism to become active. It is converted to thio-inosine monophosphate (TIMP) by the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT). TIMP is then further metabolized to active thioguanine nucleotides (TGNs). The active metabolites exert their cytotoxic effects via two primary mechanisms: Inhibition of Purine Synthesis: TIMP inhibits key enzymes in the de novo purine synthesis pathway, specifically glutamine-5-phosphoribosylpyrophosphate amidotransferase. This deprives the cell of the purine nucleotides (adenine and guanine) required for DNA and RNA synthesis. Incorporation into DNA/RNA: Active thioguanine nucleotides are incorporated into replicating DNA and RNA chains. Because these sulfur-containing nucleotides are structurally abnormal, their incorporation disrupts nucleic acid structure, leads to DNA strand breaks, and triggers cell cycle arrest and apoptosis. This effect is most pronounced in rapidly dividing cells, such as leukemic blasts and activated lymphocytes. Pharmacokinetics & Genetic Variations Oral absorption of Mercaptopurine is highly variable and incomplete, with an average bioavailability of approximately 16% (range 5% to 37%). Food, particularly milk products containing xanthine oxidase, can significantly reduce its absorption. Peak plasma concentrations are reached 1 to 2 hours post-dose. Plasma protein binding is low (approximately 19%). The elimination half-life from plasma is short (1 to 2 hours), but the active intracellular metabolites have a much longer half-life, supporting once-daily dosing. Mercaptopurine is metabolized via three primary pathways, and genetic variations in these pathways are clinically significant: Thiopurine Methyltransferase (TPMT): TPMT inactivates 6-MP. Patients with inherited TPMT deficiency (about 1 in 300 individuals are homozygous deficient) cannot metabolize the drug normally, leading to very high levels of active TGNs and severe, life-threatening bone marrow suppression. Genetic testing for TPMT activity is recommended prior to initiating therapy. NUDT15: Inherited variations in the NUDT15 gene also lead to increased risk of severe myelosuppression and alopecia. This variant is more common in patients of East Asian and Hispanic descent. Xanthine Oxidase (XO): XO converts 6-MP to inactive 6-thiouric acid. Co-administration of allopurinol (an XO inhibitor) blocks this pathway, significantly increasing 6-MP exposure. The dose of 6-MP must be reduced to 25% to 33% of the standard dose when co-administered with allopurinol. Clinical Indications & Dosage Mercaptopurine is indicated for the treatment of acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen. It is also widely used off-label for the maintenance of remission in moderate to severe Crohn’s disease and ulcerative colitis. The standard starting oral dose for pediatric and adult ALL is 1.5 to 2.5 mg/kg once daily, usually taken on an empty stomach in the evening. Dosing is adjusted based on hematological response and tolerability, with close monitoring of white blood cell and platelet counts. In patients with known TPMT or NUDT15 deficiency, starting doses must be reduced (often by 90% for homozygous deficient patients) to avoid severe toxicity. Warnings & Safety warnings Mercaptopurine is a highly toxic drug requiring careful clinical monitoring: Myelosuppression: The most common dose-limiting toxicity is bone marrow suppression, leading to anemia, leukopenia, thrombocytopenia, and an increased risk of serious infections. Weekly blood counts are required during initiation. Hepatotoxicity: Can cause liver dysfunction, including cholestasis, portal hypertension, and hepatic necrosis. Liver function tests must be monitored regularly, and therapy should be suspended if bilirubin or transaminases rise significantly. Carcinogenicity: Long-term use of immunosuppressive doses is associated with an increased risk of developing secondary malignancies, including lymphoma and hepatosplenic T-cell lymphoma, especially in young male patients with IBD. Frequently Asked Questions Why should I avoid milk when taking Mercaptopurine? Cow’s milk contains high levels of xanthine oxidase, an enzyme that degrades Mercaptopurine in the digestive tract. Taking the medication with milk can significantly reduce its absorption and clinical efficacy. Do I need genetic testing before starting 6-MP? Yes, testing for TPMT and NUDT15 genotype or phenotype is highly recommended before starting Mercaptopurine. It identifies patients at high risk for severe, life-threatening bone marrow suppression, allowing for personalized, safe dosing.